

Research Compliance Activity and Turn-Around-Time (TAT) Summary Report
Fiscal Year 2021 (7/1/2020 to 6/30/2021)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Institutional Biosafety Committee (IBC) - Bloomington								
	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median
Full Board								
New Studies - Full Board (to review)	25.4	23.0	26.0	26.0	31.3	33.5	26.8	30.0
New Studies - Full Board (to approval)	48.5	42.0	41.2	41.2	42.5	36.0	44.0	46.0
Exempt								
New Studies - Exempt (to determination)	22.4	20.0	24.0	15.5	41.75	38.0	33.7	34.0
Amendments								
Amendments - Minor	5.4	1.0	5.4	2.0	5.5	1.0	2.5	0.0
Amendments - Major	26.0	26.0	24.4	19.0	34.3	35.5	20.3	17.0

*Note: TAT includes a "pre-review" time frame occurring prior to full committee meeting.

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged
New Studies - Full Board	7	11	4	3	5	2	3	4	1	7	3	-4 (57.1%)
New Studies - Exempt	5	4	-1 (20.0%)	3	4	1	5	4	-1 (20.0%)	4	3	-1 (25.0%)
Amendments - Minor	44	41	-3 (6.8%)	31	33	2	38	39	1	51	50	-1 (2.0%)
Amendments - Major	6	2	-4 (66.7%)	5	7	2	3	4	1	6	8	2
Continuing Reviews	26	34	8	27	30	3	23	23	0	30	27	-3 (10.0%)
TOTAL	88	92	4 (-4.5%)	69	79	10 (-14.5%)	72	74	2 (-2.8%)	98	91	-7 (7.1%)

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	0	0	0	1	1

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0	0	0	0	0
30 Day OBA Report	0	0	1	0	1
Lab Accident/Injury/Exposure	0	0	0	1	1

Reporting Agency: NIH Office of Biotechnology Activities (OBA)